Aurora Payments Appoints Embedded Commerce Leader John Badovinac
Badovinac joins Aurora to lead the expansion of embedded payments across software platforms, ISVs, and ecommerce channels
John Badovinac - Senior Vice President of Embedded Commerce
LAS VEGAS, May 01, 2025 (GLOBE NEWSWIRE) -- Aurora Payments, a full-service payment technology provider, today announced the appointment of John Badovinac as Senior Vice President of Embedded Commerce. A proven leader in the payments space, Badovinac will oversee Aurora's embedded and integrated payments strategy, with a focus on accelerating growth through ISV, SaaS, and ecommerce partner ecosystems
Badovinac brings over 25 years of go-to-market experience across the full spectrum of payments services, including integrated ISV payments, merchant acquiring, value-added resellers, EMV certification, and point-of-sale systems.
'John is a respected leader in the integrated payments space with deep relationships and a unique understanding of how to bring value to software platforms and partners,' said Derek Dean, CRO at Aurora Payments. 'His ability to drive strategy while building trusted, long-term partnerships will be instrumental as we expand our embedded commerce capabilities.'
Prior to joining Aurora, Badovinac led the B2B Channel at Fortis, where he was responsible for business strategy, revenue growth, and partner success across the company's ISV and VAR segments. He also held senior roles at International Bancard, TSYS, and Discover Financial Services, where he played a foundational role in developing integrated payments solutions and establishing go-to-market motions with ISVs and payment facilitators.
Badovinac joins Aurora at a pivotal moment as the company continues to scale its ARISE platform, expand its partner ecosystem, and bring seamless, intelligent payments infrastructure to ISVs, vertical SaaS providers and traditional businesses alike.
'What drew me to Aurora is the team's bold vision, the strength of the platform, and the opportunity to truly enable software platforms to grow revenue,' said Badovinac. 'I'm thrilled to join an organization of proven and decisive leaders that are committed to innovation and to building meaningful relationships with its partners.'
This appointment marks the latest investment in Aurora's leadership team, following the recent addition of Avin Arumugam as Chief Product Officer and Derek Dean as Chief Revenue Officer.
About Aurora Payments
Aurora Payments is a united network of processing, technology, and payments solutions, supporting over 27,000 merchants and $12 billion in annual processing volume. Founded in 2005, Aurora has carved out leadership in several industries through its innovative products, exceptional service, and deep vertical expertise. The company's proprietary platforms —ARISE, RISE CRM, Calendarise, and NailSoft—are cloud-based solutions designed to simplify payments and operations for small and midsize businesses. Headquartered in Las Vegas, Aurora Payments is backed by Corsair, a leading private equity firm focused on payments, software, and financial service investments.
Follow Aurora Payments on LinkedIn or X, or learn more at https://risewithaurora.com.
ContactsMedia Contacts:Dominic LittenSVP, Marketing and Partnerships+1 2165132935Dom.Litten@risewithaurora.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8127d210-49f2-4a49-84a1-0e0257335550Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Why Oklo Inc. (OKLO) Soared On Wednesday
We recently published a list of . In this article, we are going to take a look at where Oklo Inc. (NYSE:OKLO) stands against other best-performing stocks. Shares of Oklo rallied for a fourth consecutive day on Wednesday, adding 2.49 percent to close at $55.24 apiece as investors cheered its partnership with a Korean company for the deployment of its advanced nuclear technology. In a statement, Oklo Inc. (NYSE:OKLO) said it signed a memorandum of understanding with Korea Hydro & Nuclear Power, a subsidiary of Korea Electric Power Corporation, to explore opportunities aimed at jointly advancing the standard design development and verification of Aurora powerhouses, manufacturability and constructability assessments, major equipment planning, as well as supply chain development. Copyright: nexusplexus / 123RF Stock Photo The collaboration also supports Oklo Inc.'s (NYSE:OKLO) deployment of a 75-MWe Aurora powerhouse at the Idaho National Laboratory site, which is currently undergoing a licensing process. Additionally, Oklo Inc. (NYSE:OKLO) plans to file follow-on applications to support its growing order pipeline, which exceeds 14 GW. Overall, OKLO ranks 9th on our list of best-performing stocks. While we acknowledge the potential of OKLO, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OKLO and that has 10,000x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ('Cartesian' or the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors. 'With the first participant now successfully enrolled, commencement of our Phase 3 AURORA trial represents a significant milestone in our mission to deliver a differentiated, durable treatment option to patients with MG,' said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. 'With sustained benefits observed through 12 months in our Phase 2b trial, we believe Descartes-08 has the potential to transform the current MG treatment paradigm with just a single course of therapy.' 'Marked by chronic use of steroids and other immunosuppressants while often delivering only limited efficacy, the current standard of care for patients with MG is inadequate,' said James (Chip) F. Howard, Jr., M.D., Cartesian Clinical Advisor and Professor of Neurology, Medicine, and Allied Health at the University of North Carolina School of Medicine. 'Supported by compelling results from the Phase 2b trial, I firmly believe that Descartes-08 has the potential to serve as a safe, flexible, and durable treatment option for patients with MG. I look forward to helping advance this important study.' The Phase 3 AURORA trial is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 participants with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo. In April 2025, the Company announced updated efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with MG. After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in the MG-ADL score at Month 12. The deepest and most compelling sustained responses were observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12. The safety profile of Descartes-08 was consistent with previously reported data and continues to support outpatient administration. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Forward Looking Statements Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding observations and data from the Company's clinical trials, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, the ability of the Company's product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, Descartes-15, or any of the Company's other product candidates to treat myasthenia gravis, systemic lupus erythematosus, juvenile dermatomyositis, multiple myeloma, or any other disease, the anticipated timing or the outcome of the FDA's review of the Company's regulatory filings, the Company's ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company's clinical trials and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'hypothesize,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial, whether results of early clinical trials will be indicative of the results of later clinical trials, and whether results observed in certain patient subgroups will be indicative of the results in such subgroups in later clinical trials or are reflective of a product candidate's overall characteristics, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company's technology, potential delays in enrollment of patients, undesirable side effects of the Company's product candidates, its reliance on third parties to conduct its clinical trials, the Company's inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company's recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company's common stock, risks related to geopolitical conflicts and pandemics and other important factors discussed in the 'Risk Factors' section of the Company's most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward looking statements included in this press release, except as required by law. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Media Contact:David RosenArgot in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Cytek Biosciences, Inc. (CTKB) Elevates Cell Analysis with New Aurora Evo System
Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on the global success of its flagship Aurora system, the new Aurora Evo introduces high-throughput and automation features designed to accelerate complex cell analysis for researchers worldwide. A scientist in a lab analyzing a culture of cells affected by tumor immune evasion. The Aurora Evo system incorporates Cytek Biosciences, Inc. (NASDAQ:CTKB)'s renowned Full Spectrum Profiling (FSP) technology, which allows scientists to conduct large-scale multicolor experiments with unmatched data quality and flexibility. Key advancements include built-in small particle detection, enabling the study of extracellular vesicles, viruses, and bacteria, and an integrated plate loader for automated, high-efficiency sample processing. Its enhanced instrument standardization ensures consistent, reproducible results across labs and time, while improved electronics and optical design double sample acquisition speed. Cytek Biosciences, Inc. (NASDAQ:CTKB)'s CTO, Dr. Ming Yan, highlighted the system's potential to revolutionize immunology and single-cell research, emphasizing its performance, reliability, and ease of use. The Cytek Aurora Evo will debut at CYTO 2025, where live demonstrations will showcase its capabilities to the scientific community. While we acknowledge the potential of CTKB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CTKB and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
